Aerska
Aerska is a biotechnology company focused on developing RNA interference (RNAi) medicines to treat neurological diseases. Leveraging its proprietary antibody-oligo conjugate (AOC) platform, Aerska aims to overcome the challenges of delivering genetic medicines across the blood-brain barrier. The company is advancing precision medicine strategies targeting genetic forms of Alzheimer's and Parkinson's diseases, with the goal of achieving durable gene silencing in the central nervous system (CNS). Headquartered in Dublin with research operations in London, Aerska is at the forefront of CNS therapeutics innovation.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $21M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $21M
- Latest Funding Round
- Seed Round
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Seed Round | $21.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Ada Ventures | Seed Round |
| Backed VC | Seed Round |
| Speedinvest | Seed Round |
| Age1 | Seed Round |
| Blueyard | Seed Round |
| Lingotto | Seed Round |
| Norrsken VC | Seed Round |
| Kerna | Seed Round |
Similar Companies
A snapshot of private companies similar to Aerska, helping you discover and navigate related company profiles.
Related News and Analysis
